|Articles|June 6, 2017

Spray Dry Technology for Pharmaceutical Development

Author(s)Catalent

With the acquisition of Pharmatek Laboratories, Catalent now offers spray drying as part of its bioavailability toolkit, complementing its comprehensive suite of development and formulation solutions.

 

From early phase development through to clinical manufacturing scale, spray drying can assist in overcoming formulation and development challenges.

 

With the acquisition of Pharmatek Laboratories, Catalent now offers spray drying as part of its bioavailability toolkit, complementing its comprehensive suite of development and formulation solutions. Additionally, the expansion of development and clinical manufacturing capabilities strengthens Catalent’s ability to partner with customers earlier in pre-clinical development.

 

Pharmatek’s San Diego facility expands Catalent’s global network of clinical and commercial manufacturing supply facilities, which integrates drug development and delivery for both oral and injectable dose forms. The site has the capacity to provide rapid development from prototype to optimal final dose form, with integrated characterization, analytical, pre-formulation, formulation, process development, and cGMP manufacturing. The facility has over 18,000 square feet of laboratory, manufacturing and support space dedicated to development and manufacturing of highly-potent compounds.

 

Spray drying technology will now be incorporated into OptiForm® Solution Suite, Catalent’s award-winning screening platform, to assess optimal formulation pathways for the oral delivery potential of both small and large molecule drugs.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.